Inovio Pharmaceuticals’ (INO) Overweight Rating Reiterated at Piper Sandler

Piper Sandler restated their overweight rating on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a report issued on Monday,Benzinga reports. The firm currently has a $4.00 price target on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on INO. Weiss Ratings upgraded shares of Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. HC Wainwright reduced their price objective on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating on the stock in a report on Monday, June 1st. Finally, Wall Street Zen cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Inovio Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $3.25.

Inovio Pharmaceuticals Stock Performance

Shares of INO opened at $0.68 on Monday. The stock has a 50-day simple moving average of $1.08 and a 200-day simple moving average of $1.33. The stock has a market capitalization of $55.70 million, a PE ratio of -0.47 and a beta of 1.52. Inovio Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. Analysts predict that Inovio Pharmaceuticals will post -0.99 EPS for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new position in Inovio Pharmaceuticals in the first quarter valued at approximately $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $234,000. Jane Street Group LLC boosted its holdings in shares of Inovio Pharmaceuticals by 221.2% in the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 27,329 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Inovio Pharmaceuticals by 1,667.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 61,516 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.